HeartBeam (BEAT) Stock Soars After FDA Clearance: Latest News, Forecasts and Analyst Views
HeartBeam shares surged 92% to $1.55 on December 10 after the company won pivotal FDA clearance for its cable-free, at-home 12-lead ECG synthesis software. Trading volume topped 270 million shares, with market cap near $53 million by midday December 11. The clearance allows manual assessment of non-life-threatening arrhythmias in adults using synthesized ECGs outside clinics.